Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Anshul Bhalla, MD"'
Autor:
Jiten P. Kothadia, MD, Anshul Bhalla, MD, Miklos Z. Molnar, MD, PhD, Rahul Mohan, MD, Vasanthi Balaraman, MD, Manish Talwar, MD, Ryan Helmick, MD, Corey Eymard, MD, Ian Clark, MD, Richa Jain, MD, Thomas W. Faust, MD, MBE, Jason M. Vanatta, MD, James D. Eason, MD, Satheesh P. Nair, MD
Publikováno v:
Transplantation Direct, Vol 8, Iss 6, p e1342 (2022)
Background. Long-term liver outcome in hepatitis C virus (HCV)-negative kidney recipients who acquired HCV infection from viremic donors is of intense interest in the transplant community. We evaluated the incidence of fibrosis in liver biopsy specim
Externí odkaz:
https://doaj.org/article/8eb7e105f346446aa61a464ecf9d255a
Autor:
Yousuf Kyeso, MD, Anshul Bhalla, MD, Alyssa P. Smith, BSc, Yaqi Jia, MPH, Safa Alakhdhair, MS, Stephanie C. Ogir, BA, Mohammad Abuzeineh, MD, Daniel C. Brennan, MD, Sami Alasfar, MD
Publikováno v:
Transplantation Direct, Vol 7, Iss 6, p e703 (2021)
Background. Donor-derived cell-free DNA (dd-cfDNA) has generated interest as a biomarker for kidney injury including transplant (KT) rejection. It is possible that the KT biopsy procedure can cause the release of dd-cfDNA, therefore affecting the rel
Externí odkaz:
https://doaj.org/article/5a69230ac7d142caa74a9819fc322baa
Autor:
Laila Lakhani, MD, Sami Alasfar, MD, Anshul Bhalla, MD, Amtul Aala, MD, Avi Rosenberg, MD, Darin Ostrander, PhD, Megan D. Schollenberger, CRNP, Daniel C. Brennan, MD, Evan J. Lipson, MD
Publikováno v:
Transplantation Direct, Vol 7, Iss 2, p e656 (2021)
Background. Donor-derived cell-free DNA (dd-cfDNA) is a useful biomarker of rejection that originates from allograft cells undergoing injury. Plasma levels
Externí odkaz:
https://doaj.org/article/e02840545ee648d781169d28b71c5848